FDA Warning Letters to Peptide Sellers: What They Say

Since 2019, the FDA has issued warning letters and untitled letters to various companies that are manufacturing or selling BPC-157. This page records all publicly available enforcement actions, the citations in each letter and the pattern of enforcement. These are the FDA warning letters peptides like BPC-157 have triggered since the agency began targeting the market.

FDA Warning Letters About Peptides

What a Warning Letter Is

A notice of warning from the FDA represents a formal declaration that it discovered some violations of the federal law after carrying out an inspection or probe. This does not mean that someone has to pay a fine, be banned from some activities, or arrested. The letter orders the recipient to rectify the situation within a certain period of time, which is usually estimated at about 15 business days. If the necessary response is not made, a recipient of the warning letter may face a series of consequences, including injunctions, seizure, and suing. All warning letters published by the FDA can be found on its enforcement page.

Two Types of Enforcement Targets

Warning letters belong to a couple of classifications. Firstly, they are directed at companies selling research chemicals such as BPC-157 and making claims about their health benefits, which qualifies the product as a drug. The second type of warning letter is sent to compounding establishments that use BPC-157 as an active pharmaceutical ingredient without proper permits. Violations may be distinct, but both originate from the fact that BPC-157 is not an approved drug.

Complete List of FDA Actions Citing BPC-157

What the Letters Tell Us

Pattern 1: Health Claims Override Research Labels

An example that best illustrates one of such cases is a letter of Warrior Labz (June 2023). The company labeled BPC-157 "for research purposes only" on the product page. However, the same website included claims about BPC-157 being able to "protect organs," prevent gastric ulcers, and reduce inflammation. The FDA used those claims as the proof of intent to sell the drug in accordance with the requirement 21 U.S.C. § 321(g)(1). The fact that the product was labeled as for research use did not provide a valid argument due to the conflicting claims made on the company's website.

Pattern 2: Compounding Without Authorization

Each correspondence from PD Labs, Tailor Made, Guyer Institute, and Barclay/Pillai highlights identical fundamental infringement; the use of BPC-157 in compounding as a bulk drug substance when it fails to be on the 503A bulks list, lacks a USP/NF monograph, and is absent in any authorized drugs. This is a clear infraction in terms of regulations. The pharmacies were merely processing prescriptions using a prohibited substance and making no health claims whatsoever.

Pattern 3: Enforcement Is Accelerating

The pace of warning letters has increased sharply. One letter in 2019. One in 2020. One in 2021. Two in 2023. One in 2024. Five in 2026. The five letters in 2026, with three issued on the same day (August 24, 2026), suggest a coordinated enforcement campaign. The FDA appears to be systematically working through the peptide vendor market.

What Happens After a Warning Letter

Company Response Options

When a company gets a warning letter, it usually reacts in one of the three ways: compliance (removal of products, addition of disclaimers, discontinuance of compounding), negotiation (disputing certain violations but implementing corrections), or non-compliance (getting silent about the letter). The majority of companies usually opt for some kind of compliance. The FDA keeps track of the reactions and announcements as cases are settled.

Escalation

The FDA has the right to use court orders to ban firms from continuing its operations if they refuse to take corrective measures. The drugs can also be seized with the help of the courts, as firms may be subjected to compliance agreements supervised by court authorities. However, criminal cases against peptide companies are rare. Nevertheless, the FDA has enforced the law against compounding pharmacy companies in the past.

1. Warning letter issued Company has 15 business days to respond
2. Response received FDA reviews corrective action plan
3. Follow-up inspection FDA verifies compliance
4. Case closed or escalated Compliance closes the case; non-compliance leads to injunction, seizure or prosecution

Implications for the Market

Vendor Behavior Changes

Certain vendors have reacted to the regulatory trend by eliminating health claims from their sites, incorporating more obvious disclaimers for their research purpose claims, or using less specific peptide products. Other vendors, meanwhile, have kept going as before as the market has not vanished, but the legal situation has become more complex.

Compounder Behavior Changes

Certain compounding pharmacies ceased distributing BPC-157 post-receiving warning letters or observing letters dispatched to rival businesses. Diverse forms of BPC-157, nonetheless, have become popular among some pharmacies, who interpret the PCAC's recommendation 8-6 as a sign that the FDA is going to allow it in the future.